Pregled bibliografske jedinice broj: 1022477
Above What Age Should Ibrutinib Not Be Given With R-CHOP to Patients With Non-GBC DLBCL?
Above What Age Should Ibrutinib Not Be Given With R-CHOP to Patients With Non-GBC DLBCL? // Journal of clinical oncology, 37 (2019), 28; 2583-2585 doi:10.1200/jco.19.01048 (međunarodna recenzija, pismo uredniku, znanstveni)
CROSBI ID: 1022477 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Above What Age Should Ibrutinib Not Be Given With R-CHOP to Patients With Non-GBC DLBCL?
Autori
Skelin, Marko ; Lucijanić, Marko ; Miketić, Tanja
Izvornik
Journal of clinical oncology (0732-183X) 37
(2019), 28;
2583-2585
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, pismo uredniku, znanstveni
Ključne riječi
ibrutinib ; non-GBC DLBCL
Sažetak
Results of the PHOENIX trial suggested significant interactions between age, treatment arm, and outcomes in non-GBC DLBCL patients treated with ibrutinib. In this letter to the editor we have addressed potential flaws of PHOENIX trial analysis and highlighted potential safety concerns of ibrutinib use in this specific population.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Ustanove:
Opća bolnica Šibenik,
Klinička bolnica "Dubrava"
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE
